학술논문
KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
Document Type
Article
Author
Kaddu-Mulindwa, D.; Regitz, E.; Held, G.; Poeschel, V.; Lesan, V.; Bittenbring, J.T.; Thurner, L.; Pfreundschuh, M.; Christofyllakis, K.; Stilgenbauer, S.; Bewarder, M.; Rixecker, T.M.; Altmann, B.; Ziepert, M.; Loeffler, M.; Robrecht, S.; Hallek, M.; Fischer, K.; Tausch, E.; Truemper, L.; Schmitz, N.; Hoth, M.
Source
In: The Lancet Haematology . (The Lancet Haematology, February 2022, 9(2):e133-e142)
Subject
Language
English
ISSN
23523026